AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05479955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 60 minutes skin to skin contact
Description: Skin-to-skin contact is defined as placing a naked baby on the mother's bare stomach or breast for at least one hour immediately after birth. In line with the recommendation of the World Health Organization, 60 minutes of skin-to-skin contact was applied to the women in this group.
Study NCT05414279 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Sodium determination
Description: Through a single finger prick 10 drops of capillary blood will be drawn. The venous blood sample will be taken through a standard venipuncture. Both samples will be send to the lab for indirect sodium determination
Study NCT04810676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501, D745, D150
Description: QD, PO
Study NCT04810676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-383
Description: QD, PO
Study NCT06077123 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contigo Application
Description: Contigo, a smartphone application, aims to achieve two main objectives: monitoring cancer patients for early detection of oncology drug toxicity signs and providing educational content to empower patients in handling clinical challenges tied to their diagnosis and treatment. Monitoring involves modules and sub-modules where patients input experiences through oncology-related questionnaires. Weekly checks for chemotherapy toxicity-associated symptoms use a validated questionnaire (PRO-CTCAE). Severe toxicity triggers immediate alerts, while milder cases receive educational guidance. Data collected is shared with healthcare providers. Educational health content has been created by professionals, encompassing cancer-specific topics, healthcare processes, administration, health coverage, self-awareness, and self-care practices. The content is based on scientific evidence, official reports, and group sessions involving healthcare professionals and cancer patients.
Study NCT06173973 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Kenetik; Ketone Concentrate
Description: Ketone Supplement
Study NCT06173973 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Isocaloric dextrose placebo
Description: Drink that is taste and visually matched to Ketone supplement
Study NCT03280186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: The minimally invasive surgical treatment methods and new techniques will be adopted such as spinal superselective angiography, preoperative embolization, intraoperative electrophysiological monitoring, intraoperative angiography, etc.
Study NCT05237609 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: rehabilitation with muscle strengthening + Oral Nutritional Supplements
Description: Combination of protein intake and muscle strengthening exercises for the improvement of walking capacities, patients in the experimental group
Study NCT05237609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation with muscle strengthening
Description: Physical activity with only muscle strengthening
Study NCT05230693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sarcoidosis Patient Assessment and Resource Companion App
Description: The first group, called the SPARC group will be asked to download the SPARC app onto the participant's smartphone, will be shown how to use the app, and then will be asked to use the app to do guided meditations for ten minutes twice a day
Study NCT04483206 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo ASCT
Study NCT04483206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT04483206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05545865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vine to Bar Chocolate covered almonds
Description: Measure the response 2 and 6 hours post chocolate covered almond intake
Study NCT06177821 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rezum®
Description: Rezum® Water vaporization device
Study NCT00105846 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Home care telemedicine
Study NCT05652907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSD201
Description: Tablets for oral administration.
Study NCT05652907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matched to FSD201 for oral administration.
Study NCT05230693 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Standard Care
Description: Participants will receive education about reducing fatigue associated with sarcoidosis during a normal clinic visit.
Study NCT04020224 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amustaline/GSH pathogen reduction technology
Description: Whole blood treated with pathogen reduction technology
Study NCT05259644 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic sleeve gastrectomy
Description: Surgical procedure - laparoscopic sleeve gastrectomy.
Study NCT04020224 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Red Blood Cell Component or whole blood
Study NCT05779501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered strengths use intervention
Description: The online strengths use intervention program follows the theorized five stages of strengths use interventions: (1) preparation and commitment, (2) identification, (3) integration, (4) action, and (5) evaluation. To increase participant engagement and motivation, gamification components are embedded in several stages.~The intervention was previously tested through a feasibility and acceptability trial (NCT05474807).~The entire intervention will be delivered online via an LMS software solution.
Study NCT05259644 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conservative treatment of obesity
Description: Diet and exercise
Study NCT05779501 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waiting-list
Description: The waiting-list arm will serve as the control group, filling in only the outcome measure at the same time as the intervention group participants.~After the intervention group finishes participating in the intervention, the waiting-list participants will benefit from the same internet-delivered strengths use program.
Study NCT06185881 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: restoration of cervical carious teeth
Description: restoration of carious cervical lesions by glass ionomer
Study NCT05259644 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic gastric plication
Description: Endoscopic procedure - endoscopic gastric plication
Study NCT06185881 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: restoration of cervical carious teeth
Description: restoration of carious cervical lesions by glass ionomer
Study NCT05149131 — intervention group
Intervention type: DRUG
Intervention: ADT (Eligard®*) with or without treatment intensification
Description: Abiraterone acetate (Zytiga®) Enzalutamide (Xtandi®) Apalutamide (Erleada®) Docetaxel (Taxotere®)~\*may be substituted with leuroprolide gel, buserelin, goserelin, triptorelin, histrelin, cyproterone or degarelix
Study NCT04537364 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: combined diagnosis of renal parenchymal damage
Description: This study is an observational study to evaluate the accuracy of renal parenchymal damage combined diagnosis with no intervention. All patients from the cohort accept MRI-DWI scan，the urinary biomarkers detection, disease gene detection and DMSA scan.~1. This combined diagnosis includes MRI-DWI scan and the urinary biomarkers detection.~   MRI-DWI： All the scans are performed using the MagnetomVerio 3.0T magnetic resonance imaging system from Siemens.~   Urinary polypeptide collection: Urine samples requirements: volume between 50-100ml, specific gravity >1.010. Immunomagnetic beads isolation technique is used to collect polypeptide.~2. The reference standard is DMSA scan: Intravenous injection of 99mTC-DMSA5mCi is followed by anterior and posterior planar imaging of the renal area 1 hour later. The DMSA scan images are read by 2 trained radiologists and confirmed by the special doctor of the center for diagnosis and treatment of renal and urinary diseases at the same time.
Study NCT05675202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3525
Description: TQ-B3525 is a new PI3K α/δ Kinase inhibitor
Study NCT05483855 — intervention group
Intervention type: OTHER
Intervention: Objective 1 Only: Telehealth Satisfaction Survey
Description: Participants must complete a telehealth satisfaction survey rating their standard of care telehealth visit on a scale of 1 to 10, with 1 denoting low satisfaction and 10 denoting high satisfaction.
Study NCT06172634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dentritic cell infusion and immunecheckpoint inhibitor
Description: dentritic cell infusion and immunecheckpoint inhibitor
Study NCT05352412 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shared Decision Making Aid
Description: Patients will be randomized to the shared decision making aid intervention.
Study NCT05352412 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baseline Counseling As usual
Description: Patients will be randomized to the baseline counseling as usual.
Study NCT04467476 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various health conditions. However, its ergogenic effect still has controversial results.
Study NCT04467476 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various health conditions. However, its ergogenic effect still has controversial results.
Study NCT05881720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril / Valsartan Oral Tablet
Description: Group 1 (N = 40) received sacubitril/valsartan (target dose, 100 mg twice daily) in addition to recommended therapy according to physician's judgment.
Study NCT05881720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg
Description: group 2 received valsartan (N=40, target dose, 80 mg twice daily) in addition to recommended therapy according to physician's judgment.
Study NCT05291936 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRECISION1® for Astigmatism Contact Lenses
Description: TEST
Study NCT05291936 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyDay® Toric Soft Contact Lenses
Description: CONTROL
Study NCT05092165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylene Blue
Description: 1 mg per kilogram bolus, followed by 0.1 milligram per kilogram during renal replacement therapy
Study NCT05092165 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Usual care during renal replacement therapy
Study NCT05590000 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gemini SCS neuromodulation system
Description: This neurostimulation system is indicated as an aid in the management of chronic, intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back and leg pain, angina pectoris and peripheral vascular disease.
Study NCT04104659 — intervention group
Intervention type: DRUG
Intervention: MK 6240
Description: PET tracer, \[18F\]MK-6240 (an\[18F\]tau imaging agent,CerveauTechnologies)that has high affinity for the human phosphorylated tau deposits in AD brain offers new opportunities to investigate tau pathology.(Hostetler, Walji et al. 2016, Lohith, Bennacef et al. 2016, Walji, Hostetler et al. 2016, Lohith, Bennacef et al. 2017, Neelamegam, Yokell et al. 2017).We will evaluate this imaging agent in individuals from families with a known Autosomal Dominant Alzheimer's Disease (ADAD) mutation.~The planned dosage for \[18F\]MK-6240 is a single intravenous bolus injection of 185 MBq (5.0 mCi) in a large peripheral vein followed by a 10 mL normal saline (0.9% NaCl) flush.
Study NCT06373770 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ayres sensory integration therapy
Description: A. Jean Ayres, is a theory and practice that targets a person's ability to process and internally integrate sensory information from their body and environment. Sensory information may be visual, auditory, tactile, proprioceptive, and/or vestibular in nature. ASI uses individually tailored activities that utilize just right challenges to an individual's existing patterns of sensory processing and motor planning and encourage movement and organization of self in time and space. ASI incorporates specialized equipment and materials in purposeful and playful activities in order to improve adaptive behavior.
Study NCT06373770 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Behaviour Therapy
Description: The current treatment options for the core symptoms of autism are limited to psychosocial therapies, such as applied behavior analysis. Medications have been most effective in treating the associated behavioral symptoms of autism, though studies have examined potential benefits in some of the core symptoms of autism with certain medications, especially the repetitive behaviors often seen with this diagnosis. Risperidone and aripiprazole are currently the only medications FDA approved for symptoms associated with autism spectrum disorders, targeting the irritability often seen with this diagnosis.
Study NCT06020846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soleus Pushup Exercise
Description: Patient will be seated on a chair, his legs at 90 degrees to the floor, keep the toes, and feet flat on the ground, and move his heels up and down continuously.~4 sets of 15 minutes each,1hour total intervention time
Study NCT06020846 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treadmill walk group 2
Description: The patient will do treadmill walk at normal walking speed, 4 sets of treadmill walk for 15 minutes each, 1hour total intervention time
Study NCT06515314 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFP Specific T Cell Receptor T Cells
Description: AFP Specific T Cell Receptor T Cells On day 1, the TCR-T cells will be administered intravenously.~Drug: Fludarabine + Cyclophosphamide Fludarabine: 25mg/m²/day×3days; Cyclophosphamide: 250mg/m²/day×3 days
Study NCT05510661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Export Catheter
Description: Manual thrombus aspiration with the use of export catheter during primary PCI
Study NCT05510661 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon catheter
Description: Predilatation with balloon catheter
Study NCT05466695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 5mg/sildenafil 25 mg
Description: patients will use daily tadalafil or daily sildenafil for 2 months blood sample will be obtained before and after 2 months and also IIEF-5 score for clinical response
Study NCT05483855 — intervention group
Intervention type: OTHER
Intervention: Objective 2 Only: ArthritisPower Joint Assessment
Description: RA patients must complete a self-assessment examination of their joints using the ArthritisPower app prior to their in-office visit, where a repeat joint assessment is performed by participating physician.
Study NCT05221775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: XELOX regimen combined with GLS-010 and different doses of Lenvatinib
Study NCT04965077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Humanized Monoclonal Antibody MIL97 for Injection
Description: Dose escalation phase: The patients confirming to the eligibility criteria will be assigned to the 6 dose groups (0.01mg/kg, 0.03mg/kg, 0.1mg/kg, 0.2mg/kg, 0.3mg/kg 0.45mg/kg, respectively) based on the sequence of inclusion. Each patient will receive an intravenous infusion of MIL97 every 3 week on Day 1 of each cycle. Additional 1 or 2 dose cohorts will receive an intravenous infusion of MIL97 every 2 week on Day 1 of each cycle after last patient finishes DLT observation period.~Dose expansion phase: One or two recommended expansion doses (either Q3W or Q2W) will be selected from 6 dose groups (0.01mg/kg, 0.03mg/kg, 0.1mg/kg, 0.2mg/kg, 0.3mg/kg 0.45mg/kg) based on results of dose escalation phase. MIL97 will be administered via intravenous infusion for 60 to 90 minutes on Day 1 of each cycle.
Study NCT06070558 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI with Real Time MRI Rapid Flash sequence
Description: MRI examination of temporomandibular joint with Real Time MRI Rapid Flash sequence
Study NCT05933629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online EmReg
Description: A Web-based group intervention to improve emotion regulation in individuals with traumatic brain injury (TBI). Online EmReg is a 3-hour on-demand training workshop
Study NCT05933629 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online EmReg
Description: A Web-based group intervention to improve emotion regulation in individuals with traumatic brain injury (TBI). Online EmReg is a 3-hour on-demand training workshop
Study NCT05933629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consultation Sessions
Description: 3 months of bi-weekly consultation sessions
Study NCT05449275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Faradic current
Description: The most common Electrical stimulation applied for foot drop is faradic current. Faradic current provides the strength and improvement to volitational muscles and increase the coordination and reduce spasticity.
Study NCT05449275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ankle foot orthosis
Description: AFO is most commonly used technique but it also has some disadvantage mainly is the movement in limited direction and also in development of contractures and may have the problem in standing from chair
Study NCT05736939 — intervention group
Intervention type: OTHER
Intervention: Out-patient Pulmonary Rehabilitation
Description: Pulmonary Rehabilitation (PR) programme consisting of 30 minutes interval aerobic exercise on cycle ergometers at 100% of peak work rate (WRpeak) and resistance exercises for the upper body. Dyspnoea and leg discomfort were recorded on the modified 1-10 Borg scale, whereas heart rate (HR) and oxygen saturation (SpO2%) were monitored by a pulse oximeter. Based on symptoms of breathlessness and fatigue reported at the end of each session, the exercise intensity was increased by 5-10% of the baseline WRpeak in the next session. The remote 24 home-based PR sessions consisted of 30 minutes walking with an individualised target of steps, recorded via the mobile app installed in the patients' mobile phone. The steps, leg discomfort and dyspnoea were reported by the patient via a physical activity diary on a weekly basis. If dyspnoea and fatigue were both \<4 at the Borg scale the weekly target of steps was increased by 5-10% by the assessors.
Study NCT04751097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CUSH Health Digital platform
Description: Remote mobility monitoring and physiotherapy video app
Study NCT06213337 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot care training with virtual classroom
Description: Providing foot care training once every two weeks in virtual classes created via the Google meet application.
Study NCT06213337 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot care training with SMS support
Description: Total of 60 SMS messages containing foot care information will be sent, one every day.
Study NCT06213337 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot care training with virtual classroom and SMS support
Description: Providing foot care training once every two weeks in virtual classes created via the Google meet application. Furthermore, total of 60 SMS messages containing foot care information will be sent, one every day.
Study NCT06477549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: Days -7 through -6: Bendamustine 90 mg/m2 iv x 2 days
Study NCT06477549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruxolitinib
Description: Days -7 through -2: ruxolitinib 5 mg tid per os
Study NCT04482413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AstroStem
Description: Treatment group receive AstroStem(Autologous adipose tissue derived mesenchymal stem cells, AdMSCs) every 4 weeks from Week 0 to Week 36.
Study NCT04482413 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control group receive 20 mL of Saline and auto serum every 4 weeks from Week 0 to Week 36.
Study NCT04885673 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vapotherm
Description: flow rate 50 L/min with 100% humidified oxygen and the temperature adjusted to be 38℃
Study NCT04885673 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Apneic oxygenation
Description: Standard apneic oxygenation through the side port of rigid bronchoscope during the procedure
Study NCT04952792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 milligram Oral Tablet
Description: Apixaban 2.5mg/12h, oral, 28 days